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Objective: Acromegalic patients display a distinct neuropsychological profile and suffer
from chronic physical complaints. We aimed to investigate in more detail these aspects
in acromegalic patients, dependent on influencing factors like disease activity, age, sex,
chronic medication, surgery, pituitary radiation, pituitary insufficiency and comorbidities.
Design: Cross sectional, multicentric.
Methods: 129 patients (M/W 65/64, 58.3 ± 12.7 years, 53/76 with active/controlled
disease). Acromegalic patients completed the following inventories: NEO-FFI, IIP-D,
and the Giessen Complaints List (GBB-24), after written informed consent. Age, sex,
IGF-1 concentrations, comorbidities, treatment modalities and pituitary insufficiency were
documented.
Results: Acromegalic patients or specific patient-subgroups were more agreeable,
neurotic, exploitable/permissive, introverted/socially avoidant, non-assertive/insecure,
nurturant and less open to experience, cold/denying, domineering, compared to normal
values from the healthy population (controls). Multivariable analysis demonstrated that
these overall results were due to the specific patient subgroups as patients on chronic
medication, with arthrosis and pituitary insufficiency. Disease activity was only associated
with the trait nurturant. Higher scores for introversion were associated with arthrosis.
Lower domineering was independent of any disease- or treatment related variable
or comorbidity. The GBB inventory showed overall higher scores in patients, with
higher scores for exhaustion and general complaints being associated with pituitary
insufficiency, coronary heart disease and history of malignancy in the multivariable
analysis. Joint complaints were independent of any disease- or treatment- related
variable.
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Conclusions: We define new aspects of a distinct neuropsychological profile in patients
with acromegaly, which are largely independent of disease activity. Chronic physical
complaints are more pronounced in patients than in controls, with exhaustion and general
complaints showing no association with disease activity.
Keywords: neuropsychological profile, physical complaints, acromegaly, disease activity, pituitary insufficiency
INTRODUCTION
Treatment goals in acromegaly are the achievement of hormonal
control and remission of symptoms, removal of the adenoma
with preservation of pituitary function, the cure of comorbidities,
the prevention of recurrence and the improvement in quality of
life (1–3).
Patients with acromegaly have been reported to display
specific personality traits and physical complaints. Sievers et al.
compared patients with acromegaly with patients with pituitary
adenomas and healthy controls. They reported that patients
with acromegaly were more avoidant, neurotic and socially
conformant, and suffered from anticipatory worries, pessimism
and fear of uncertainty, fatigability and asthenia, compared to
healthy controls. These traits were also encountered in patients
with pituitary adenomas. However, a reduced impulsiveness and
novelty seeking behavior was specific for acromegalic patients
and was independent of age, sex, adenoma type, treatment
modality, pituitary insufficiency and hormonal control (4).
Neuropsychological alterations can negatively impact on
other domains like quality of life, cognitive function and
subjective well-being. Interestingly, many chronic alterations
in patients with acromegaly persist despite hormonal control.
Previous studies reported a reduced quality of life even if
biochemical control has been reached (5–8). This might be
due to joint-related comorbidities (9) or previous radiotherapy,
which in turn can lead to social isolation, reduced motivation,
depression and anxiety (10, 11). Recent data showed that
reduction in quality of life is associated with depression and
anxiety rather than with biochemical control or other possible
predictors like age, sex, tumor size, disease duration, treatment
type and comorbidities (5).
Pereira et al. observed that, compared to subjects with
other pituitary tumors, schwannomas or chronic pain, patients
with acromegaly displayed more cognitive impairment and
personality disorders. In addition, one third of these patients
were diagnosed with anxiety and depression. These findings
were common for patients with active and controlled disease
with long-lasting remission, and possibly caused by irreversible
alterations of the central nervous system due to long term growth
hormone (GH) excess or by residual disabilities like chronic
arthrosis-associated pain (12, 13).
Besides these alterations, well-being in acromegalic patients
may be negatively affected by a variety of complaints. Patients
with acromegaly revealed worse scores on physical functioning,
reduced activity, vitality, and general health perception, if they
needed postoperative treatment with long-acting somatostatin
analogs (6). Furthermore, joint problems were not related to GH
and IGF-1 levels, active disease duration, or age (9). Long-term
cured acromegaly patients had high pain scores of the spine, knee
and hip which limited physical functioning (14).
Based on the current literature, it is not clear which
factors influence these alterations of personality, mood
and physical wellbeing. Therefore, we aimed to analyze
in a comprehensive multi-center non-interventional study
personality, relationship patterns and physical complaints in 129
patients with acromegaly, compared to standardized manual
data and the impact of influencing factors like age, sex, disease
activity, pituitary insufficiency, disease duration, treatment
variables and comorbidities on these parameters.
PATIENTS AND METHODS
Study Design
This is a cross-sectional multicenter non-interventional study,
conducted at the Department of Endocrine and Metabolic
Diseases, 1st Medical Clinic and Polyclinic, University of
Mainz, Germany. Patients were recruited from six German
endocrine centers. Inclusion criteria were: age >18 years,
diagnosis of acromegaly, willingness to participate in the
study, written informed consent. Exclusion criteria were:
psychiatric disorder; psychiatric medication (antidepressants,
antipsychotics, sedatives); excessive alcohol consumption (>30
g/day in men and >20 g/day in women) or drug addiction;
pregnancy or lactation; a language barrier.
Patients
The patients were seen either in the outpatient Dept. of
Endocrinology and Metabolic Diseases Mainz or in one of
the other five cooperating centers for a standardized clinical
assessment with physical examination and laboratory testing.
The patients were asked at a regular follow-up visit to complete
three questionnaires. Additional information was documented
by the physician regarding age, sex, acromegaly status with
definition of disease activity: hormonally uncontrolled (before
or under treatment); and hormonally controlled (under or
after treatment). Hormonal control was defined according to
consensus guideline recommendations as GH levels <1 µg/l
during a glucose tolerance test over 2 h and IGF-1 levels in the
age- and sex-matched normal range (2) and was applied as such
in all participating centers. Treatment was defined as surgery,
chronic medication against GH-excess or pituitary radiation.
Further data were: age at diagnosis; secretion pattern (GH excess
only or mixed GH and prolactin overproduction); current IGF-
1 value (ng/ml), current or previous treatment of GH excess
with duration (surgery, medication, radiotherapy), comorbidities
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(coronary heart disease, arterial hypertension, diabetes mellitus,
cancer history, arthrosis); current medication and dosage,
including hormonal treatment for coexisting pituitary deficiency.
The data were documented in an anonymized form.
The project was approved by theMedical Ethics Committee of
the University of Mainz. All patients provided written informed
consent. We included 129 patients, fulfilling the above criteria.
Hormonal Measurements
To avoid methodological and assay differences among the
participating centers, a single additional serum sample was
collected from each patient during routine laboratory testing.
This was frozen at −20◦C and sent to the University of Mainz
for standardized measurement of IGF-1 in the Institute for
Clinical Chemistry and LaboratoryMedicine. In our center, IGF1
measurement of all samples has been performed with the IGF1
kit from Siemens on a Siemens Immulite 2000 device, with a
chemiluminescence immunoassay method.
Psychological Assessment
NEO-FFI is a psychological personality inventory developed by
Costa and McCrea, containing in its original form five subscales
investigating neuroticism, extraversion, openness to experience,
agreeableness and conscientiousness. The inventory contains 12
items/subscales and a total of 60 items, scored between 0 and
4. The results were interpreted and compared to the general
population based on the manual’s data (15).
IIP-D is a self-reported instrument that identifies
interpersonal problems. We used the short form of the
German version with 64 items, based on a circumplex
model evaluating control/dominance- and fondness. The
following characteristics were analyzed: domineering;
vindictive/competing; cold/denying; introverted/socially
avoidant; non-assertive/insecure; exploitable/permissive;
nurturant (i.e., relating to the fact of taking care of or the ability
to do so, in both a physical and emotional manner); intrusive
(i.e., a typically unwelcome behavior, interrupting and disturbing
to others) (16). The score for each item ranged between 0
and 4. The sum of the scale value was divided by the number
of items/subscale to obtain the normed individual subscale
value. For comparison with the general population we used
standardized data from the handbook, based on a representative
German sample of individuals aged between 14 and 98 years.
The overall individual IIP-value was obtained by the sum of all
eight scales, divided by eight.
Assessment of Physical Complaints
The Giessen Subjective Complaints List (GBB-24) quantifies
physical complaints grouped in four subscales: exhaustion (E),
gastric (G), joint (J), and heart (H) complaints. Each subscale
comprises six questions which are ranked from 0 to 4. The highest
subscale value and herewith the highest degree of the specific
complaint can be 24. The sum of all subscales yields the general
complaints score (total GBB) and can reach from 0 to 96. The
inventory was standardized using a sample of 2,182 subjects aged
18–60 years, representative for the German population. The scale
norms were also subdivided according to sex and age (17).
Controls
The inventory results of the patients were compared to normative
values of the general population, which are provided by the
respective inventory-manual in the form of age- and sex-specific
means and standard deviations for each subscale (controls).
Statistical Analysis
Statistical analyses were subdivided into three parts: First,
inventory results were compared to manual-based normative
values of the general population (controls; see above). In each
subgroup being defined by age and sex, the patient’s score was
compared to the respective mean for the general population by
performing a one sample t-test (for normally distributed data) or
a sign test (for not normally distributed data).
Second, we examined differences between the general
population (normal manual data for the healthy population;
controls) and several patient-subgroups that were prescribed
by binary disease- or comorbidity-related variables (such as
active vs. controlled disease, surgery yes/no, radiation yes/no,
etc.). To adjust for age and sex as confounders within these
comparisons, the patients’ subscale-values were transformed to
Z-scores by subtracting the mean and dividing by the standard
deviation of the respective normative age-/gender-subgroup.
For comparisons between patient-subgroups (being defined
by disease- or comorbidity-related variables) and the general
population, we analyzed if the patients’ Z-scores deviate from
zero by using a one-sample Wilcoxon signed rank test.
Third, we compared the patients among each other by
using multivariable linear regression analysis (MV). For each
questionnaire we used the main subscale-scores as well as
the total score (where available) as the respective dependent
variable. As explanatory variables, we considered those that
are linked to the disease/disease activity (active vs. controlled
status, medication, surgery, radiation, pituitary insufficiency) and
variables to control for confounding due to comorbidities -
such as coronary heart disease, arterial hypertension, diabetes,
history of malignancy and arthrosis. Regression techniques were
used to assess if modeling assumptions were fulfilled. For each
multivariable regression model, we present the coefficients along
with 95% confidence intervals and the p-values of a two-sided
test.
Statistical analyses were performed with the R environment
for statistical computing and graphics, version 3.4.4 (R Core
Team, 2017). Our complete data analysis is exploratory. For
all tests we used a 0.05 level to define subgroup-differences as
statistically noticeable and relevant. However, due to the large
number of tests, p-values should be interpreted with caution and
in connection with effect estimates.
RESULTS
The patients’ characteristics of the 129 included patients are
presented in Table 1. The distribution in the four groups,
according to the hormonal activity and treatment status at
the time of evaluation was: uncontrolled before any treatment
(n = 17, 13%, IGF-1 = 719.8 ± 281.9 ng/ml); uncontrolled
under treatment (chronic medication against GH-excess; n= 36,
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TABLE 1 | Patients characteristics.
Parameters Distribution
Age (years) 58.3 ± 12.7 (30–86)
Time since diagnosis (years) 13.4 ± 8.1 (0–23)
M/F 65/64
GH/GH and prolactin 120/9
Active disease/biochemical control 53 (41.1%)/76 (58.9%)
Complete/partial pituitary
insufficiency
10 (7.8%)/37 (28.7%)
thyreotrope insufficiency (n = 27),
corticotrope insufficiency (n = 20),
gonadotrope insufficiency (n = 23)
Treatment 112 (yes)/17 (no)
Pituitary surgery 104/112; 92.9%; > 1 surgery (n = 17/112;
15.2%)
Medication 68/112 (60.7%)
Somatostatin analogs: 36 (32.1%)
Dopamin agonists: 7 (6.3%)
Pegvisomant: 2 (1.8%)
Secvential or combined: 23 (20.5%)
Radiotherapy 16/112 (14.3%)
Comorbidities Arthrosis: 69/129 (53.5%)
Arterial hypertension: 47/129 (36.4%)
Diabetes mellitus: 20/129 (15.5%)
Coronary heart disease: 16/129 (12.4%)
History of malignancy: 13/129 (10.0%)
Continuous data are presented as mean ± 1 standard deviation (range), categorical data
are presented as counts/ number of subjects (%).
28%, IGF-1 = 417.8 ± 224.9 ng/ml); controlled under treatment
(chronic medication against GH-excess; n = 27, 21%, IGF-
1 = 177.6 ± 73.1 ng/ml); controlled after treatment (surgery
± radiation, chronic medication; n = 49, 38%, IGF-1 = 175.9
± 66.1 ng/ml). Some patients had more than one comorbidity.
The most common comorbidity was arthrosis (53.5%), followed
by arterial hypertension (36.4%), diabetes mellitus (15.5%),
coronary heart disease (12.4%), and a history of malignancy
(10%).
Neuropsychological Profile, According to
the NEO-FFI Inventory
The relevant age- and sex-specific differences between all patients
with acromegaly, irrespective of hormonal activity, and controls
are given for the NEO-FFI inventory in Table 2. Male patients
aged 30–49 years had higher scores of agreeableness (p = 0.005),
while male patients older than 50 years and female patients older
than 30 years showed a lower openness to experience p = 0.024
and p < 0.001, respectively).
To gain more insight into the differences between patients
and controls, we performed an age- and sex- independent
analysis with Z-score calculations, considering the following
parameters: disease activity, surgery, pituitary radiotherapy,
medication for disease control, pituitary insufficiency,
comorbidities (coronary heart disease, arterial hypertension,
diabetes mellitus, history of malignancy, arthrosis). Differences
among patients, considering the abovementioned parameters,
including also age and sex, were explored by multivariable
analysis (MV).
A subgroup comparison, according to the specified variables
showed that patients on chronic medication had higher scores
of agreeableness than controls, independent of age and sex
(p = 0.008; Figure 1: 1). No relevant differences were seen
between patients not meeting these criteria and controls.
Among patients, the MV of the NEO-FFI inventory showed
lower openness to experience in those with history of malignancy
(p= 0.047) (Supplementary Table 1).
A further subgroup analysis showed higher neuroticism scores
in hormonally controlled patients having at least one pituitary
insufficiency compared to those without pituitary insufficiency
(22.0 ± 6.4 vs. 18.7 ± 7.4, p = 0.042). Neuroticism was also
higher in hormonally controlled female patients with at least
one pituitary insufficiency, compared to those without pituitary
insufficiency (22.9 ± 7.0 vs. 18.1 ± 7.2, p = 0.044) and between
female patients with controlled disease on specific medication
(somatostatin analogs/dopamine agonists/pegvisomant) and
those with controlled disease without chronic medication (21.2
± 7.2 vs. 17.8 ± 7.1, p = 0.054). Furthermore, female patients
with at least one pituitary insufficiency had lower values for
agreeableness (29.9 ± 5.6 vs. 35.0 ± 4.6, p = 0.007) compared
to female patients without pituitary insufficiency (data not
shown). Since dopamine agonists can cause neuro-psychological
adverse effects themselves, we subdivided patients on chronic
medication in those who received dopamine agonists (n= 7, all in
combination with SSA) and those who did not receive dopamine
agonists in their treatment regimen (n= 61). Neuroticism scores
were 21.6 ± 6.6 in the dopamine-subgroup and 21.1 ± 6.2 in the
patients not receiving dopamine agonists (p= 0.884).
Taken together, the NEO-FFI showed that younger male
patients had higher scores of agreeableness while older male
patients and younger female patients demonstrated a lower
openness to experience.
Neuropsychological Profile, According to
the IIP-D Inventory
Table 3 shows the relevant differences of parameters of the
IIP-D-inventory between patients and controls, according to
age and sex. Male patients aged 35–44 years were more
exploitable/permissive than controls (p = 0.011), while female
patients of this age groupweremore introverted/socially avoidant
(p < 0.001). Male and female patients aged 45–54 years were less
domineering than controls (p = 0.031 for men and p = 0.017
for women). Of note, there were no obvious differences in this
inventory between patients and controls aged 55–64 years, nor in
those older than 65 years (13 female patients, no male patients,
219 controls; data not shown).
A subgroup comparison, according to the mentioned
variables, revealed that patients with pituitary insufficiency were
less cold/denying (p = 0.034), patients who received pituitary
radiation were more introverted/socially avoidant (p = 0.027)
and patients on chronic medication or suffering from arthrosis
were more non-assertive/insecure than controls (p = 0.029 and
0.044, respectively), independent of age and sex. Furthermore,
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TABLE 2 | Age- and sex-specific differences between patients and controls based on the NEO-FFI inventory.
Age (years) Parameter Males Females
Patients Controls p Patients Controls p
30–49 Neuroticism 21.10 ± 9.3 18.8 ± 7.8 0.274 19.76 ± 7.4 22.04 ± 8.28 0.131
n males = 25 patients /1035 controls) Extraversion 25.52 ± 8.1 26.82 ± 6.66 0.471 28.93 ± 4.9 27.87 ± 6.41 0.280
n females = 28 patients/1992 controls) Openness to experience 30.19 ± 5.0 30.68 ± 6.56 0.712 26.81 ± 4.9 31.34 ± 6.15 <0.001
Agreeableness 31.81 ± 4.0 29.02 ± 5.1 0.005 32.61 ± 5.7 31.1 ± 5.2 0.182
Conscientiousness 31.48 ± 7.3 31.41 ± 6.86 0.967 34.0 ± 6.0 32.43 ± 6.54 0.196
≥50 Neuroticism 19.19 ± 6.6 19.5 ± 7.15 0.893 20.98 ± 5.4 21.83 ± 7.7 0.376
n males = 42 patients/403 controls Extraversion 24.01 ± 5.7 25.43 ± 6.15 0.129 26.21 ± 4.9 27.1 ± 6.15 0.308
n females = 34 patients/713 controls Openness to experience 26.47 ± 6.2 28.84 ± 6.12 0.024 27.03 ± 4.3 29.97 ± 6, 1 <0.001
Agreeableness 30.71 ± 4.9 29.54 ± 4.97 0.154 32.82 ± 5.5 32.1 ± 4.8 0.432
Conscientiousness 32.39 ± 5.6 33.37 ± 5.97 0.291 34.64 ± 5.5 33.1 ± 5.6 0.118
Continuous data are presented as mean ± 1 standard deviation. P < 0.05 defined subgroup-differences as statistically noticeable and relevant.
FIGURE 1 | Z scores (mean/median) for different neuropsychological traits and physical complaints, which differed from controls in an age- and gender- independent
comparison, with respect to disease- and treatment associated factors as well as comorbidities. Z-score formation implies that values of age- and sex-matched
controls would be 0 in mean/median. 1—agreeable in patients on chronic medication (Z = 0.31 ± 0.90); 2—cold/denying in patients with pituitary insufficiency
(Z = −0.24 ± 0.83); 3—introvert/socially avoidant in patients who received pituitary radiation (Z = 0.34 ± 0.74); 4—non-assertive/insecure in patients (a) on chronic
medication (Z = 0.27 ± 0.93), (b) with arthrosis (Z = 0.25 ± 0.96); 5—exploitable/permissive in patients (a) on chronic medication (Z = 0.28 ± 0.99), (b) with arthrosis
(Z score = 0.20 ± 0.88); 6—nurturant in patients with (a) active disease (Z = 0.28 ± 0.94), (b) on chronic medication (Z = 0.28 ± 0.9), (c) with arthrosis (Z = 0.26 ±
0.85); 7—gastric complaints in patients with (a) active disease (Z = 0.51 ± 1.33), (b) on chronic medication (Z = 0.51 ± 1.33), (c) with history of malignancy (Z = 1.33
± 1.28), (d) with arthrosis (Z = 0.34 ± 0.95), (e) with pituitary insufficiency (Z = 0.77 ± 1.47); 8—heart complaints in patients (a) with active disease (Z = 0.77 ± 1.15),
(b) on chronic medication (Z = 0.58 ± 1.21); 9, total GBB in patients with comorbidities overall (Z = 0.89 ± 1.27).
scores for exploitability/permissiveness were higher in patients
on chronic medication (p = 0.022) or in those suffering
from arthrosis (p = 0.047), compared with controls. The trait
nurturant was more pronounced in patients with active disease
(p = 0.021), on chronic medication (p = 0.009) and in those
suffering from arthrosis (p = 0.009), in the age- and sex-
independent comparison with controls (Z scores in Figure 1: 2–
6). No differences were seen between patients not meeting these
criteria and controls.
Among the patients, those suffering from arthrosis were more
introverted/socially avoidant (p = 0.022), as shown by MV
(Supplementary Table 2).
Taken together, the IIP-D Inventory demonstrated age specific
differences between AP and controls. The younger female
patients showed more introvertion/social avoidance, while
younger male patients were more exploitable/permissive. The
middle aged group was significantly less domineering.
Physical Complaints, According to the
GBB Inventory
The GBB inventory has been completed only by 124/129 patients.
In patients younger than 40 years, exhaustion was higher in
patients than controls for both sexes, while joint and heart
complaints were more often described in female patients. With
increasing age exhaustion, joint and heart complaints were
higher in patients. Finally, in those over 60 years of age gastric
and joint complaints were increased in patients compared to
controls, while exhaustion was higher only in male patients.
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TABLE 3 | Age- and sex-specific differences between patients and controls based on the IIP-D inventory.
Age (years) Parameter Males Females
Patients Controls p Patients Controls P
35–44 Domineering 0.99 ± 0.5 1.12 ± 0.66 0.335 1.24 ± 0.7 1.04 ± 0.65 0.341
n males = 17 patients /255 controls Vindictive/competing 0.19 ± 0.4 1.13 ± 0.63 0.560 0.96 ± 0.7 1.01 ± 0.55 0.811
n females = 17 patients/316 controls Cold/denying 1.27 ± 0.6 1.21 ± 0.64 0.719 1.14 ± 0.68 0.96 ± 0.5 0.117
Introverted/socially avoidant 1.59 ± 0.8 1.23 ± 0.74 0.112 1.27 ± 0.76 0.82 ± 0.3 <0.001
Non-assertive/insecure 1.76 ± 1.0 1.32 ± 0.76 0.121 1.23 ± 0.5 1.46 ± 0.78 0.791
exploitable/permissive 1.78 ± 0.6 1.34 ± 0.68 0.011 1.56 ± 0.5 1.49 ± 0.68 0.612
Nurturant 1.73 ± 0.6 1.47 ± 0.66 0.137 1.60 ± 0.5 1.57 ± 0.65 0.285
Intrusive 1.22 ± 0.6 1.19 ± 0.65 0.849 1.42 ± 0.7 1.20 ± 0.62 0.285
45–54 Domineering 0.86 ± 0.6 1.17 ± 0.67 0.031 0.63 ± 0,5 1.01 ± 0.62 0.017
n males = 23 patients/196 controls Vindictive/competing 0.99 ± 0.4 1.10 ± 0.58 0.815 0.80 ± 0.4 1.01 ± 0.61 0.128
n females = 17 patients/222 controls Cold/denying 1.16 ± 0.6 1.24 ± 0.71 0.609 0.93 ± 0.5 1.10 ± 0.67 0.231
Introverted/socially avoidant 1.35 ± 0.8 1.27 ± 0.75 0.662 1.16 ± 0.8 1.24 ± 0.72 0.710
Non-assertive/insecure 1.41 ± 0.7 1.35 ± 0.78 0.694 1.66 ± 0.6 1.48 ± 0.79 0.354
Exploitable/permissive 1.43 ± 0.5 1.36 ± 0.61 0.568 1.60 ± 0.5 1.43 ± 0.66 0.265
Nurturant 1.45 ± 0.4 1.50 ± 0.57 0.589 1.52 ± 0.5 1.53 ± 0.58 0.952
Intrusive 1.00 ± 0.5 1.16 ± 0.60 0.195 0.92 ± 0.5 1.20 ± 0.58 0.064
55–64 Domineering 1.03 ± 0.9 1.10 ± 0.65 0.759 0.95 ± 1.0 1.03 ± 0.64 0.581
n males = 18 patients /232 controls Vindictive/competing 1.40 ± 0.7 1.10 ± 0.59 0.127 0.92 ± 0.7 0.98 ± 0.60 0.879
n females = 17 patients /293 controls Cold/denying 1.46 ± 0.8 1.26 ± 0.68 0.382 0.98 ± 0.8 1.22 ± 0.68 0.092
Introverted/socially avoidant 1.47 ± 0.8 1.24 ± 0.68 0.277 1.34 ± 0.6 1.31 ± 0.75 0.870
Non-assertive/insecure 1.57 ± 0.8 1.43 ± 0.73 0.530 1.61 ± 0.9 1.50 ± 0.74 0.647
Exploitable/permissive 1.58 ± 0.7 1.44 ± 0.65 0.057 1.66 ± 0.8 1.55 ± 0.68 0.631
Nurturant 1.64 ± 0.5 1.52 ± 0.58 0.180 1.77 ± 1.0 1.62 ± 0.61 0.598
Intrusive 1.13 ± 0.7 1.19 ± 0.58 0.771 1.15 ± 0.9 1.22 ± 0.60 0.798
Continuous data are presented as mean ± 1 standard deviation. P < 0.05 defined subgroup-differences as statistically noticeable and relevant.
Heart complaints at this age were comparable to controls. Total
GBB scores were overall higher in patients, except male patients
younger than 40 years (Table 4).
In the age- and sex- independent comparison between
patients and controls, according to disease-specific factors and
comorbidities, we noticed that gastric complaints were more
pronounced in patients with active disease (p = 0.023), on
chronic medication (p = 0.045), with a history of malignancy
(p = 0.005), with arthrosis (p = 0.032) and with pituitary
insufficiency (p = 0.003), compared with controls. Heart
complaints in patients exceeded those found in controls, when
the disease was active (p < 0.001) or chronic medication was
present (p = 0.002). No relevant differences were seen between
patients not meeting these criteria and controls. The total
GBB-value was higher in patients with comorbidities overall
(p < 0.001) (Figure 1: 7–9).
MV revealed that among patients, exhaustion was more
pronounced in those with pituitary insufficiency (p= 0.015) and
coronary heart disease (p = 0.009) (Supplementary Table 3). A
history of malignancy was associated with more heart complaints
(p = 0.006). Higher total GBB scores were registered in patients
with pituitary insufficiency (p = 0.043), and a history of
malignancy (p = 0.034). Interestingly, a history of pituitary
surgery or sellar radiotherapy was not associated with more
physical complaints among patients, nor was disease activity
associated with exhaustion, joint complaints or the total GBB
score.
Taken together the GBB inventory demonstrated less sex
differences than seen in the previous tests. Complaints increased
by age with exhaustion being the leading complaint throughout,
while gastric, joint and heart complains increased age-related.
Beyond 40 years of age the total GBB score was higher at each
age group compared to normal values.
DISCUSSION
Our multicenter study in acromegalic patients found specific
personality characteristics and relationship patters. Overall,
patients suffered from a high somatic symptom load.
Neuropsychological Profile, According to
the NEO-FFI and the IIP-D Inventories
The analysis of the neuropsychologic profile confirmed some
already described traits and identified new elements. Patients
or specific subgroups were less open to experience, more
agreeable, permissive and introvert and less domineering,
compared to manual normal values for the healthy population.
Lower openness to experience was associated with a history
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TABLE 4 | Age- and sex-specific differences between patients and controls based on the GBB inventory.
Age (years) Parameter Males Females
Patients Controls P Patients Controls P
≤40 years Exhaustion 9.71 ± 7.04 2.52 ± 3.8 0.035 8.75 ± 5.84 3.32 ± 3.8 0.034
n males = 9 patients/255 controls Gastric complaints 1.28 ± 1.11 1.52 ± 2.6 0.59 6.0 ± 5.34 1.76 ± 2.8 0.060
n females = 11 patients/316 controls Joint complaints 5.82 ± 3.48 3.31 ± 3.8 0.101 8.87 ± 3.68 4.0 ± 3.9 0.007
Heart complaints 1.0 ± 1.52 1.19 ± 2.7 0.75 4.25 ± 3.45 1.3 ± 2.4 0.046
Total score 17.85 ± 10.73 8.53 ± 11.11 0.061 27.8 ± 15.9 10.38 ± 11.1 0.017
40–59 years Exhaustion 7.86 ± 4.61 3.18 ± 3.7 <0.001 10.13 ± 7.20 4.21 ± 4.5 <0.001
n males = 20 patients/196 controls Gastric complaints 2.91 ± 2.60 2.26 ± 3.0 0.24 3.03 ± 3.5 2.16 ± 3.0 0.118
n females = 35 patients/222 controls Joint complaints 8.82 ± 2.60 4.89 ± 4.1 0.003 9.83 ± 6.39 6.35 ± 4.6 0.006
Heart complaints 3.65 ± 3.15 1.88 ± 3.0 0.013 5.13 ± 4.46 2.27 ± 3.3 0.002
Total score 23.26 ± 13.57 12.2 ± 11.8 0.001 27.93 ± 18.65 14.9 ± 13.0 0.001
>60 years Exhaustion 9.0 ± 5.11 4.69 ± 4.2 0.001 7.77 ± 5.45 6.17 ± 4.4 0.091
n males = 21 patients/232 controls Gastric complaints 4.08 ± 2.59 2.74 ± 3.4 0.021 4.28 ± 4.69 2.44 ± 3.2 0.026
n females = 19 patients/293 controls Joint complaints 9.39 ± 4.94 6.89 ± 4.1 0.024 10.57 ± 5.59 8.48 ± 4.7 0.034
Heart complaints 4.21 ± 3.24 3.39 ± 3.7 0.235 4.51 ± 4.05 3.78 ± 3.7 0.281
Total score 26.69 ± 12.10 17.71 ± 13.1 0.002 26.85 ± 17.16 20.70 ± 13.3 0.041
Continuous data are presented as mean ± 1 standard deviation. P < 0.05 defined subgroup-differences as statistically noticeable and relevant.
of malignancy. Lower dominancy was not associated with any
disease variable, treatment modality or comorbidity, suggesting
possibly an intrinsic disease-associated personality alteration.
Only introversion associated with one comorbidity in MV
(arthrosis).
Our large acromegalic cohort displayed significantly lower
scores for openness to experience in the NEO-FFI inventory
and thus confirmed data from Sievers et al. who conducted a
cross sectional study on 70 acromegalic patients. Their patients
had a psychological profile that could be similarly observed
in patients with non-functioning pituitary adenomas. However,
patients with GH-producing adenomas showed specific traits like
lower impulsiveness and reduced novelty seeking behavior (4).
Previous data pointed to increased rates of affective disorders
in acromegaly. Affective disorders were found in 34.6% of the
patients with acromegaly, compared to 21% of patients with
and 11% of those without chronic somatic disorders. Rates were
even higher in those acromegalic patients who needed additional
treatment after surgery (18). The same authors showed that
depression and anxiety negatively impacted quality of life in
acromegaly (5).
Neuroticism scores tended to be higher in our female patients
who needed specific medication for disease control vs. those
who reached control without chronic medication. Furthermore,
female patients with at least one pituitary insufficiency had
lower values for agreeableness. Specific data allowing a direct
comparison of the neuropsychological profile in female patients
with acromegaly, in the light of influencing factors, are not
available. However, female sex predicted a negative result for all
scales except the appearance domain of the Acromegaly Quality
of Life Questionnaire, according to Vandeva et al. (10).
An age- and sex- independent comparison between patients
and controls revealed a less denying personality in patients
with pituitary insufficiency. Among our hormonally controlled
patients, neuroticism scores were higher in those having at
least one pituitary insufficiency. Few previous investigations
addressed the issue of concomitant pituitary deficiencies in
acromegaly and all of these explored quality of life issues.
Wexler et al. showed a significantly impaired quality of
life in GH-deficient patients after treatment of acromegaly
compared to GH-sufficient patients, as measured by the QoL-
AGHDA, the Symptom Questionnaire Depression and SF36
questionnaires (19), while Vandeva et al. found that the absence
of hypopituitarism independently predicted improvements in
quality of life (10).
Disease activity had little impact on the observed
neuropsychological changes in our study; only the score for
the trait nurturant was higher in patients with active disease
compared to controls, without further alterations in the
psychological items of the NEO-FFI or the IIP-D inventory.
There are few literature data analyzing the association of
neuropsychological traits and disease activity. Ruchala et al.
described some improvement of interpersonal relations under
treatment with octreotide, with intensive repression of emotions
(20). Current evidence suggests that a longterm cure or control
of the disease activity does not necessarily improve the quality of
life (21). Biermasz et al. was the first to report reduced general
perceived well-being and quality of life in a cross-sectional
study including 118 successfully treated acromegalic patients
(8). A recent meta-analysis of published data revealed that
disease-activity reflected by biochemical control measures
yielded mixed, and therefore inconclusive results with respect to
their effect on QoL (22). Sardella et al. suggested that successful
treatment, resulting in complete remission, improved quality
of life in acromegalic patients in the short term, at 6 months.
However, the lack of correlation between the ACROQOL score
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after 24 months might suggest that factors like serum IGF-1
concentration play a role in determining the well-being of
acromegalic patients (7).
It is not clear why psychological alterations are not limited to
the duration of increased GH-exposure but persist in cured or
controlled patients. Possible explanations for these findings may
be related to alterations in the macroscopic brain architecture
with increased global, left and right hippocampal gray matter and
white matter volumes at the expense of cerebral spinal fluid (23,
24), as demonstrated in cerebral MRI. These persistent structural
alterations could explain, at least in part, our neuropsychological
findings, which were mainly independent of disease activity.
Physical Complaints, According to the
GBB Inventory
Comorbidities and pain are frequent in acromegaly. In our
cohort, exhaustion and general complaints were more severe
in patients than controls and were associated with pituitary
insufficiency, a history of malignancy and coronary heart disease
in the MV. Disease activity had no impact on exhaustion and
general complaints, while joint complaints were not relevantly
associated with any disease- or treatment-related variables or
comorbidities. This suggests again that other factors, besides
disease activity, and possibly long-term irreversible effects of
GH-excess could be involved in the persistence of chronic
complaints.
In line with this, in a retrospective, multicenter cohort
study including 131 acromegalic patients within the German
Pegvisomant Observational Study, perspiration, soft tissue
swelling and perceived health improved after 1 year of
pegvisomant therapy, while other symptoms such as headache,
fatigue and joint pain remained largely unchanged over time,
suggesting irreversible damage despite treatment (25).
Arthrosis occurred in 53.5% of patients, arterial hypertension
in 36.4%, diabetes mellitus in 15.5% and coronary heart disease
in 12.4%, while a history of malignancy was reported in 10%
of patients. In the literature, among 118 patients in long-term
remission after treatment, with a mean duration of remission
of 12.0 ± 7.4 years, self-reported joint problems occurred
in 77%, hypertension in 37%, diabetes mellitus in 11%, and
a history of myocardial infarction in 9%. In accordance to
our findings, the joint problems were not related to disease
activity or age, previous or current disease-specific treatment.
It has been already reported that joint complaints had a
significant negative impact on the quality of life (9). Chronic pain
appears to be a frequent problem in acromegaly. Investigating
81 acromegalic patients, a high prevalence of bodily pain
(65%) and headache (65%), with an increased nociceptive
pain component (80%) was found, without significant impact
of modifiable factors like tumor size, genetic predisposition,
previous surgery, irradiation or medical therapy, but with
significant correlations with depression and quality of life
(26).
A limitation of our study is the lack of a concurrent, real-
life control group. However, we analyzed the psychologic and
physical parameters based on manual data, with comparison
to representative groups from the healthy general population.
Due to the low prevalence of the disease, it was not possible to
include more patients, despite the multi-center design. A further
limitation is the cross-sectional, non-prospective design.
In conclusion, our multicenter study provides an extensive
characterization of psychological traits, relationship patterns
and subjective complaints in patients with acromegaly, with
analysis of the impact of disease-modifying factors. The distinct
neuropsychological profile and physical complaints are largely
not dependent on hormonal control and seem to be in part
disease specific, possibly due to long term GH excess, in part
associated with chronic comorbidities. Concurrent pituitary
insufficiency negatively impacts both the psychological profile
and physical complaints.
Knowledge of the neuropsychological profile and subjective
symptoms in view of the influencing factors could facilitate
a more individual approach to patients with acromegaly and
improve the care of disease-related aspects.
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